• Mashup Score: 0

    There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with…

    Tweet Tweets with this article
    • Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices [May 23, 2018] @JLErsek @lorablk @mtmdphd @DrEdKim #ASCO18 Educational Book https://t.co/UJqfs6bPXf https://t.co/zL49RwxYl7

  • Mashup Score: 0

    There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with…

    Tweet Tweets with this article
    • Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices [May 23, 2018] @JLErsek @lorablk @mtmdphd @DrEdKim #ASCO18 Educational Book https://t.co/UJqfs6bPXf https://t.co/86dSjkZXaq

  • Mashup Score: 0

    Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment. Several high-quality studies confirm that more than 50% of all patients with cancer experience moderate to severe pain. The prevalence of pain in cancer survivors is estimated to be 40%, while close to two-thirds of those with advanced disease live with pain. Progress has occurred in the…

    Tweet Tweets with this article
    • Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives | American Society of Clinical Oncology Educational Book https://t.co/xI3YYXonsr

  • Mashup Score: 0

    Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with HER2 alterations: somatic mutations and amplifications. HER2 was first assessed as a biomarker of resistance to anti-EGFR therapy; however, in more…

    Tweet Tweets with this article
    • Drs. @SelmaAhcenedjab, Francesca Daniel, Anna Milani, @giammi107 & @lonardi_sara cover #HER2 inhibition as an effective treatment strategy in refractory #MetastaticColorectalCancer ➡️ https://t.co/PcIMWWn5WD #ASCOEdBook #crcsm https://t.co/bUGVHVAEqo

  • Mashup Score: 2

    Adults compose nearly half of all patients diagnosed with acute lymphoblastic leukemia (ALL) and historically have had poor survival compared with pediatric patients. Recently approved therapies, such as monoclonal antibodies, CAR T-cell constructs, and next-generation tyrosine kinase inhibitors, have improved survival in relapsed and refractory ALL, and studies are now examining incorporating…

    Tweet Tweets with this article
    • Read Drs. @ECurranMD, @LoriMuffly & @LuskinMarlise's review on how novel agents & management approaches for ALL diagnosed in adults of all agents are transforming outcomes! https://t.co/AfJE4meeur #ASCOEdBook #leusm

  • Mashup Score: 2

    The 1960 discovery of the Philadelphia chromosome in chronic myeloid leukemia (CML) marked the beginning of the modern genomic era of oncology. In the following years, the molecular underpinnings of CML were unraveled, culminating in the development of the first molecularly targeted therapy: imatinib. Imatinib revolutionized CML management, inducing deep molecular responses for most patients and…

    Tweet Tweets with this article
    • ❔ There are now 6 TKIs for #CML—but which to choose first? Read the #ASCOEdBook review by Drs. @kristenpettitmd, @a_razzle, Ehab L. Atallah & Jerald Radich: https://t.co/BgUtF3ZIFh #ASCO22 #MPNSM https://t.co/iplsXxIpOf

  • Mashup Score: 4

    Biochemical recurrence develops in almost one-third of men with prostate cancer after treatment with local therapy. There are numerous options for management, including surveillance, salvage radiation, androgen deprivation therapy (ADT), and clinical trials. This article reviews the current approaches to radiation therapy, ADT, and molecular imaging in men with biochemically recurrent prostate…

    Tweet Tweets with this article
    • Drs. Nicholas I. Simon, @PCaParker, Thomas A. Hope & @Cpaller provide an excellent overview of BCR & the role of PSMA PET imaging for prostate cancer: https://t.co/0b49Tt5bMk #ASCOEdBook #GUCSM #pcsm @theNCI @ICR_London @UCSFCancer @JohnsHopkins https://t.co/jPHQHMSbWx

  • Mashup Score: 3

    Cancer clinical trials are critical for testing new treatments, yet less than 5% of patients with cancer enroll in these trials. Minority groups, elderly individuals, and rural populations are particularly underrepresented in cancer treatment trials. Strategies for advancing equity in cancer clinical trials for these populations include (1) optimizing clinical trial matching by broadening…

    Tweet Tweets with this article
    • In this #ASCOEdBook article, Drs. @ME_Fleury, @PierceLoriJ, Carmen E. Guerra, Leslie P. Byatt & Mr. Tyler Lian propose ways to advance #equity in cancer #clinicaltrials. ➡️ https://t.co/CvcqJiR7A1 #healthequity https://t.co/s27nCFzSew

  • Mashup Score: 1

    There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with…

    Tweet Tweets with this article
    • Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices [May 23, 2018] @JLErsek @lorablk @mtmdphd @DrEdKim #ASCO18 Educational Book https://t.co/UJqfs6tqON https://t.co/neX1LF4gKu